Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Vaccines made from peptides may make the body build an effective immune response to kill tumor cells.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.
調査の概要
詳細な説明
OBJECTIVES:
Primary
- Compare the overall survival of patients with HLA-A2-positive, stage IIIB or IV or recurrent non-small cell lung cancer (NSCLC) treated with vaccine therapy comprising EP-2101 emulsified in montanide ISA-51 with that of historical controls and patients with HLA-A2-negative, stage IIIB or IV or recurrent NSCLC who undergo observation only.
- Determine the safety of this vaccine in these patients.
Secondary
- Determine progression-free survival of patients treated with this vaccine.
- Determine the frequency, magnitude, and breadth of cytotoxic and helper T-cell response to vaccine epitopes in patients treated with this vaccine.
OUTLINE: This is an open-label, multicenter study. Patients are assigned to 1 of 2 treatment groups according to HLA-A2 status.
- Group I (HLA-A2 positive): Patients receive vaccine therapy comprising EP-2101 emulsified in montanide ISA-51 subcutaneously once in weeks 0, 3, 6, 9, 12, and 15.
- Group II (HLA-A2 negative): Patients undergo observation in weeks 9 and 18. After completion of study treatment, patients in group I are followed at 3 weeks. All patients are then followed at months 1, 2, 3, 5, and 8, every 3 months for 2 years, and then annually for 2 years.
PROJECTED ACCRUAL: A total of 84 patients will be accrued for this study within 1 year.
研究の種類
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Florida
-
Ocoee、Florida、アメリカ、34761
- Cancer Centers of Florida - Ocoee
-
-
New York
-
Albany、New York、アメリカ、12208
- New York Oncology Hematology, P. C. at Albany Regional Cancer Care
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Kettering、Ohio、アメリカ、45409
- Dayton Oncology & Hematology, P.A. - Kettering
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29615
- Cancer Centers of the Carolinas - Eastside
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- Sarah Cannon Cancer Center at Centennial Medical Center
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Mary Crowley Medical Research Center at Sammons Cancer Center
-
Tyler、Texas、アメリカ、75702
- Tyler Cancer Center
-
-
Washington
-
Spokane、Washington、アメリカ、99218
- Cancer Care Northwest - North
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Histologically confirmed non-small cell lung cancer meeting 1 of the following stage criteria:
- Stage IIIB disease
- Stage IV disease
- Recurrent disease
HLA-A2-positive disease
- HLA-A2 negative patients are eligible to enroll in group II (observation) only
- Measurable disease
- Estimated tumor volume ≤ 125 cc
No CNS signs or symptoms of brain metastases
- Brain metastases that are clinically stable for ≥ 2 months AND do not require anticonvulsants or systemic steroids are allowed
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 12 weeks
Hematopoietic
- Hemoglobin ≥ 10 g/dL
- Platelet count > 100,000/mm^3
- WBC > 3,000/mm^3
- Absolute neutrophil count > 1,500/mm^3
- Absolute lymphocyte count > 500/mm^3
Hepatic
- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN for patients with liver involvement by tumor)
- Bilirubin ≤ 2.0 mg/dL (3.0 mg/dL for patients with liver involvement by tumor)
- Albumin ≥ 2.5 g/dL
- Alkaline phosphatase ≤ 2.5 times ULN
- No history of hepatitis B or C positivity
Renal
- Creatinine ≤ 2 times ULN
Immunologic
No history of any of the following active conditions:
- Systemic lupus erythematosus
- Scleroderma
- Connective tissue disease
- Sjögren's syndrome
- Multiple sclerosis
- Rheumatoid arthritis
- Inflammatory bowel disease
- No history of HIV positivity
- No history of serious adverse reaction, including anaphylaxis, or hypersensitivity to study vaccine or to any of its components
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 weeks after completion of study treatment
- No other malignancy within the past 5 years except curatively excised nonmelanoma skin cancer or surgically cured carcinoma in situ of the cervix
- No other acute medical condition that would preclude study treatment
- No mental or psychiatric condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 1 month since prior interferon therapy
- More than 1 month since prior interleukin therapy
- No prior cancer vaccine therapy, including participation in a vaccine study
Chemotherapy
- At least 4 weeks since prior chemotherapy
Endocrine therapy
- See Disease Characteristics
- More than 1 month since prior systemic corticosteroids except stable doses of inhaled corticosteroids
Radiotherapy
- At least 4 weeks since prior radiotherapy
Surgery
- Not specified
Other
- No concurrent participation in another investigational study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
安全性
|
Comparison of overall survival with historical controls
|
二次結果の測定
結果測定 |
---|
無増悪生存
|
Frequency, magnitude, and breadth of cytotoxic and helper T-cell response to vaccine epitopes
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Scott Plasman、Epimmune
研究記録日
主要日程の研究
研究開始
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
肺癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ